Posts tagged Drug-Lead Combination Products.
Blogs
6 minute read
Combination products present a tremendous opportunity to improve health outcomes, because they leverage multiple disciplines. If we were, for example, to focus on drugs alone with little thought to how they might be delivered, we would be surely missing a chance to enhance safety or effectiveness. Likewise, many devices can be made more effective or safer if paired with a drug.
At the end of 2016, FDA finalized a rule covering Postmarket Safety Reporting for Combination Products that now can be found at 21 C.F.R. Subpart B.[1] A few years later, in July 2019, FDA finalized a guidance ...
Back to Health Law Advisor Blog
Recent Updates
- Congressional Action on Health Care Cybersecurity: HISAA is Re-Introduced and the Health Care Cybersecurity and Resiliency Act Moves Forward
- DOJ Corporate Fraud Enforcement Memo: What Health Care Companies Need to Know Now
- Attorneys General of Three States File Two Sweeping Lawsuits Targeting Telehealth Abortion Providers and State Shield Laws
- RFI Seeks Input on Medicare Part D’s Pharmacy Contract Standards
- Proposed H.R. 10336 Would Balance Innovation, Access to Dietary Supplements—Yet Change the Definition